Richard Francis Sells 442,935 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) CEO Richard Francis sold 442,935 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the sale, the chief executive officer directly owned 642,099 shares of the company’s stock, valued at approximately $20,778,323.64. The trade was a 40.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $31.06 on Friday. The business’s fifty day moving average is $33.01 and its 200 day moving average is $26.20. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The company has a market capitalization of $35.71 billion, a PE ratio of 25.88, a price-to-earnings-growth ratio of 10.63 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the prior year, the business posted $0.71 earnings per share. The business’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on TEVA. Scotiabank upped their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group upped their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Barclays increased their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Finally, Piper Sandler reissued an “overweight” rating and set a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently bought and sold shares of the stock. Global Retirement Partners LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after purchasing an additional 302 shares during the last quarter. Banque Cantonale Vaudoise lifted its position in shares of Teva Pharmaceutical Industries by 6.3% in the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after buying an additional 306 shares in the last quarter. Ethic Inc. lifted its position in shares of Teva Pharmaceutical Industries by 1.8% in the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after buying an additional 325 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.